Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies-Reference-Cited by-同舟云学术

Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies

Published:2020-09-14 Issue:1 Volume:15 Page:143-152
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Calzetta Luigino¹^ORCID,Ritondo Beatrice Ludovica²,de Marco Patrizia²,Cazzola Mario²^ORCID,Rogliani Paola²^ORCID

Affiliation:

1. Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy

2. Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2020.1816830

Reference29 articles.

1. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 report. 2020 [cited 2020 Apr 22]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.

2. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

3. Adding a LAMA to ICS/LABA Therapy

4. Inhaled corticosteroids in COPD: the final verdict is…

5. Single Triple vs Dual Inhaler Therapy

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in COPD severe exacerbations, and all-cause and respiratory mortality, before and after implementation of newer long-acting bronchodilators in a large population-based cohort;BMC Pulmonary Medicine;2024-09-13

2. POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes;CHEST;2024-07

3. Triple fixed drug combination in the treatment of patients with chronic obstructive pulmonary disease;Meditsinskiy sovet = Medical Council;2024-06-05

4. New clinical guidelines for COPD – a paradigm shift: A review;Terapevticheskii arkhiv;2024-04-16

5. Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease;Expert Review of Respiratory Medicine;2023-12-02